Prestige BioPharma Limited
SGFinancials
Valuation Metrics
Prestige BioPharma Limited's Market Cap is ₩3564B. At end of 2025 it was ₩7722B. Ranked #606 of 2,419 in KR market (top 25%), #351 of 781 on KOSPI (top 45%), #64 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 28%) by Market Cap.
Investment Metrics(as of 2026-10-08)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 356.37B KRW | KR#606/2,419 Sec#64/231 |
| Revenue | 27.73B KRW | KR—/2,419 Sec—/231 |
| Net Income | -130.70B KRW | KR—/2,419 Sec—/231 |
| Total Assets | 737.79B KRW | KR—/2,419 Sec—/231 |
| Net Assets | 504.47B KRW | KR—/2,419 Sec—/231 |
| Employees | 54 | KR#2,022/2,419 Sec#185/231 |
| Value | ||
| P/B | 0.71x | KR#1,116/2,419 Sec#62/231 |
| P/S | 12.85x | KR#2,293/2,419 Sec#168/231 |
| FCF Yield | -18.44% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | -25.91% | KR—/2,419 Sec—/231 |
| ROA | -17.72% | KR—/2,419 Sec—/231 |
| Op. Margin | -359.06% | KR—/2,419 Sec—/231 |
| Revenue Growth | 99.06% | KR—/2,419 Sec—/231 |
| Earnings Growth | -3322.60% | KR—/2,419 Sec—/231 |
| Financial Health | ||
| Debt Ratio | 46.25% | KR—/2,419 Sec—/231 |
| Total Debt | 101.30B KRW | KR—/2,419 Sec—/231 |
| FCF | -65.72B KRW | KR—/2,419 Sec—/231 |
| Cash | 62.70B KRW | KR—/2,419 Sec—/231 |
| Current Ratio | 0.75x | KR—/2,419 Sec—/231 |
| Performance | ||
| 1Y Return | -54.45% | KR#2,158/2,419 Sec#202/231 |
| 1M Return | -6.61% | KR#1,902/2,419 Sec#181/231 |
| From 52W High | -58.00% | KR#1,823/2,419 Sec#149/231 |
| 1Y MDD | -63.42% | KR#1,672/2,419 Sec#140/231 |
| Trading | ||
| Volume | 19,206 shares | KR#1,657/2,419 Sec#172/231 |
| Trading Value | 114.2M KRW | KR#1,531/2,419 Sec#171/231 |
| Foreign Own. | 63.32% | KR—/2,419 Sec—/231 |
| Per Share | ||
| EPS | -2,175 KRW | KR—/2,419 Sec—/231 |
| BPS | 8,394 KRW | KR#1,108/2,419 Sec#77/231 |
Company Info
Established in 2015 and based in Singapore, Prestige BioPharma Limited operates as a biopharmaceutical enterprise. The company's activities encompass the research, development, and commercialization of biosimilars and novel antibody therapeutics, primarily targeting the Asia Pacific market. A significant focus for Prestige BioPharma is the creation of antibody-based treatments for critical conditions such as solid tumors, pancreatic cancer, breast cancer, gastric cancer, and arthritis. Furthermore, the firm is also advancing the development of vaccines for the COVID-19 virus.